Cell>Point News & Publications

Diagnostic Imaging

News

CENTENNIAL, Colo., November 23, 2011

Posted on: April 14th, 2012

Cell>Point announced today that the University of Texas M.D. Anderson Cancer Center will present pre-clinical results on Cell>Point’s therapeutic, Platinum-EC-G, for Aggressive type-B Lymphoma at the 53rd American Society of Hematology Annual Meeting December 10-13, 2011

Read More

CENTENNIAL, Colo., June 6, 2011—Cell>Point announced today that it will present Phase 2 clinical trial results for its cancer molecular imaging agent, 99mTc-EC-G

Posted on: April 14th, 2012

https://www.cellpointweb.com/2011-SNM-Final.pdf

Read More

CENTENNIAL, Colo., March 18, 2010—Cell>Point announced today that it was awarded March 15, 2011 the North American SPECT Radiopharmaceuticals Technology Innovation Award by Frost & Sullivan.

Posted on: April 14th, 2012

Read More

Cell>Point adds Dr. Wayne Yakes to Board of Advisors – 11/22/2010

Posted on: April 14th, 2012

CENTENNIAL, Colo., November 22, 2010 – Cell>Point is pleased to announce that Dr. Wayne Yakes has joined our Board of Advisors.  Dr. Yakes currently serves as the Director of the Vascular Malformation Center, Interventional Neuroradiology and Interventional Radiology – Swedish Medical Center, Englewood, Colorado.  Dr. Yakes is board certified in Radiology, Interventional Radiology and Neuroradiology…

Read More

Cell>Point to present at 52nd American Society of Hematology Annual Meeting December 4-7, 2010.

Posted on: April 14th, 2012

CENTENNIAL, Colo., December 1, 2010 – Dr. Lan V. Pham, Department of Hematophathology, The University of Texas M.D. Anderson Cancer Center, will be presenting the following paper titled “Metabolic Targeted Therapy for Aggressive B-cell Lymphomas: Evaluating Glucose Metabolism and the Potential of 187Rhenium-Ethylenedicysteine – N- AcetylGlucosamine (187Re-EC-G) for Therapy” at the 52nd American Society of Hematology Annual…

Read More

CENTENNIAL, Colo., March 18, 2010

Posted on: April 14th, 2012

Cell>Point announced today that it was awarded March 15, 2011 the North American SPECT Radiopharmaceuticals Technology Innovation Award by Frost & Sullivan.

Read More

CENTENNIAL, Colo., June 21, 2010

Posted on: April 14th, 2012

Cell>Point announced today that it has submitted to the US Food and Drug Administration (FDA) an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD).

Read More

CENTENNIAL, Colo., June 3, 2010

Posted on: April 14th, 2012

Cell>Point announced today that it will present clinical results for its cancer imaging agent, 99mTc-EC-G, used to assess the efficacy of chemotherapy at the 2010 Society of Nuclear Medicine Annual Meeting on June 7, 2010.

Read More

CENTENNIAL, Colo., February 10, 2010

Posted on: April 14th, 2012

Cell>Point announced today that M. Donald Blaufox, M.D., Ph.D, will be coordinating principal investigator for its Phase 2/3 clinical trial of99mTc-EC-G for cancer diagnostic imaging. The trial is currently underway.

Read More

Cell>Point receives approval for Beta Cell Technology patent – 6/23/2009

Posted on: April 14th, 2012

CENTENNIAL, Colo., June 23, 2009 – Cell>Point today announced that the U.S.P.T.O. approved its Beta Cell Technology U.S. patent application (App. No. 10/942,615). Cell>Point’s Beta Cell Technology is currently in preclinical testing at The University of Chicago Medical Center for imaging Type I Diabetes.

Read More